Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But what can you do? There is no pause button to stop the world from spinning. So this means one thing: time to dig in to the tasks at hand. On that note, we have assembled a menu of tidbits to help you get started. Hope your day is simply smashing and, as always, do keep in touch if something saucy arises. …

Pfizer (PFE) agreed to merge its off-patent drugs business with Mylan (MYL), betting that combining its Upjohn unit with the big generic drug maker will provide a pathway to reignite sales growth, The Wall Street Journal reports. The deal brings together two businesses whose sales have slowed since former big sellers lost patent protection and began facing lower-priced competition, but would further efforts by Pfizer chief executive Albert Bourla to focus on patent-protected prescription drugs and vaccines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!